Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
oleh: Rodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, Marc Humbert, John Mattson, Arno Fritsch, Michael Krowka
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2018-05-01 |
Deskripsi
In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.